Merck asks FDA for emergency authorization for molnupiravir, first pill to treat COVID-19


Washington — Drug maker Merck requested U.S. regulators Monday to authorize its pill in opposition to COVID-19 in what would add a completely new and easy-to-use weapon to the world’s arsenal in opposition to the pandemic.

If cleared by the Food and Drug Administration – a choice that would are available in a matter of weeks – it might be the first pill proven to treat COVID-19. All different FDA-backed remedies in opposition to the illness require an IV or injection.

An antiviral pill that folks might take at house to cut back their signs and velocity recovery might show groundbreaking, easing the crushing caseload on U.S. hospitals and serving to to curb outbreaks in poorer nations with weak well being care methods. It would additionally bolster the two-pronged method to the pandemic: therapy, by means of remedy, and prevention, primarily by vaccinations.

The FDA will scrutinize company information on the protection and effectiveness of the drug, molnupiravir, earlier than rendering a choice.

Merck and companion Ridgeback Biotherapeutic mentioned they particularly requested the company to grant emergency use for adults with mild-to-moderate COVID-19 who’re in danger for extreme illness or hospitalization. That is roughly the way in which COVID-19 infusion medicine are used.

“The value here is that it’s a pill so you don’t have to deal with the infusion centers and all the factors around that,” mentioned Dr. Nicholas Kartsonis, a senior vp with Merck’s infectious illness unit. “I think it’s a very powerful tool to add to the toolbox.”

The company reported earlier this month that the pill minimize hospitalizations and deaths by half amongst sufferers with early signs of COVID-19. The outcomes had been so sturdy that impartial medical specialists monitoring the trial beneficial stopping it early.

Side results had been related between sufferers who bought the drug and people in a testing group who acquired a dummy pill. But Merck has not publicly detailed the sorts of issues reported, which will likely be a key a part of the FDA’s review.

U.S. officers proceed to push vaccinations as one of the best ways to shield in opposition to COVID-19. But with some 68 million eligible Americans nonetheless unwilling to get the photographs, efficient medicine will likely be crucial to controlling future waves of an infection.

Since the start of the pandemic, well being specialists have harassed the necessity for a handy pill. The aim is for one thing related to Tamiflu, the 20-year-old flu remedy that shortens the sickness by a day or two and blunts the severity of signs like fever, cough and stuffy nostril.

Three FDA-authorized antibody medicine have proved extremely efficient at lowering COVID-19 deaths, however they’re costly, arduous to produce and require specialty gear and well being professionals to ship.

Assuming FDA authorization, the U.S. authorities has agreed to purchase sufficient of the tablets to treat 1.7 million folks, at a value of roughly $700 for every course of therapy. That’s lower than half the value of the antibody medicine bought by the U.S. authorities – over $2,000 per infusion – however nonetheless costlier than many antiviral tablets for different circumstances.

Merck’s Kartsonis mentioned in an interview that the $700 determine doesn’t characterize the ultimate value for the remedy.

“We set that price before we had any data, so that’s just one contract,” Kartsonis mentioned. “Obviously we’re going to be responsible about this and make this drug as accessible to as many people around the world as we can.”

Kenilworth, New Jersey-based Merck has mentioned it’s in buy talks with governments all over the world and can use a sliding value scale primarily based on every nation’s financial means. Also, the company has signed licensing offers with a number of Indian generic drugmakers to produce low-cost variations of the drug for lower-income nations.

Several different corporations, together with Pfizer and Roche, are finding out related medicine and are anticipated to report ends in the approaching weeks and months. AstraZeneca can also be in search of FDA authorization for a long-acting antibody drug supposed to present months of safety for sufferers who’ve immune-system problems and don’t adequately reply to vaccination.

Eventually some specialists predict varied COVID-19 therapies will likely be prescribed together to higher shield in opposition to the worst results of the virus.

Download our Free App

For Breaking News & Analysis Download the Free CBS News app